Please use this identifier to cite or link to this item:
https://hdl.handle.net/1/1303
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sturm, Jonathan | en |
dc.contributor.author | Crimmins, Denis | en |
dc.contributor.other | Hackett, M.L. | en |
dc.contributor.other | Carter, G. | en |
dc.contributor.other | Clarke, T. | en |
dc.contributor.other | Maddock, K. | en |
dc.date.accessioned | 2019-03-20T22:39:28Z | en |
dc.date.available | 2019-03-20T22:39:28Z | en |
dc.date.issued | 2010-02 | en |
dc.identifier.citation | Volume 5, Issue 1, pp. 52 - 56 | en |
dc.identifier.issn | 1747-4949 | en |
dc.identifier.uri | https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1303 | en |
dc.description.abstract | RATIONALE: One in three patients experience depression after stroke and this risk is consistent over time. A strategy to prevent depression that could be economically delivered to most stroke patients and ideally which also has a low likelihood of adverse events needs to be developed and evaluated. Aims POST aims to determine whether a simple intervention (postcards) prevents depression (Hospital Anxiety and Depression rating Scale, HADS depression subscale score > or =8) in patients with a recent stroke. Secondary end-points include reduced anxiety (HADS anxiety subscale score > or =8) and improved health-related quality of life in patients with a recent stroke. DESIGN: A single-centre randomised, double-blind, pilot trial to prevent depression in patients with a recent (within 8 weeks) stroke presenting to hospital. Patients will be enrolled over 12 months and randomised to receive three trial-specific assessments (baseline, 3- and 6-month assessments of mood, HRQoL and social functioning), or three trial-specific assessments plus a postcard sent centrally in a sealed envelope at 1, 2, 3, 4 and 5 months after discharge from hospital. Blinded follow-up telephone assessments will be conducted for both groups. STUDY OUTCOMES AND SAMPLE SIZE: For the primary end-point the POST trial will have 80% power to detect a relative risk of 0.4 given an incidence of depression of 30%. For the secondary aims POST has 90% power to detect a difference of 3 points on the HADS depression subscale (assuming a standard deviation of 6 points) between randomised groups. This includes an inflation factor of 15% to account for patients lost to follow-up. DISCUSSION: Evidence of efficacy will determine whether a multi-centre, international trial is warranted. | en |
dc.subject | Neurology | en |
dc.subject | Stroke | en |
dc.title | imProving Outcomes after STroke clinical pilot trial protocol | en |
dc.type | Journal Article | en |
dc.identifier.doi | 10.1111/j.1747-4949.2009.00388.x | en |
dc.description.pubmeduri | https://www.ncbi.nlm.nih.gov/pubmed/20088995 | en |
dc.identifier.journaltitle | International Journal of Stroke | en |
dc.type.studyortrial | Randomized Controlled Clinical Trial/Controlled Clinical Trial | en |
dc.originaltype | Text | en |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
Appears in Collections: | Neurology |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.